Cancer Clinical Trials

Participating in a clinical trial can be a life-changing experience. When you join a clinical trial, you not only take an active role in fighting your own cancer, but you also help researchers and scientists develop new medications and treatments to help other cancer patients live longer.

At The Christ Hospital Health Network, we are recognized as a national leader in clinical research and for best practice standards in patient care. Our research and innovation has led to breakthrough medical advances and improved outcomes for nearly 40 years.

Every day, our doctors and researchers work to find cures for cancer - but we don't do it alone. Our patients play an essential role in finding better ways to prevent, diagnose and treat cancer.

 

Promising new therapies for cancer

Our clinical trials are conducted at various locations including:

  • The Christ Hospital Cancer Center

  • The Christ Hospital Physicians - Hematology & Oncology

  • The Christ Hospital Physicians - Surgical Oncology

  • Other clinical sites throughout Greater Cincinnati

We average 15 active studies, from phase I though phase IV. Phases are steps that clinical trials go through. If a new treatment is successful in one phase, it moves on to testing in the next phase.

Search our clinical trials

Find a clinical trial that is right for you. Below is a categorized list (alphabetical by cancer type) of all of our studies updated monthly so you know you're getting the latest information available. All of the following trials are currently recruiting. To refer a patient or enroll in a currently recruiting cancer cohort, call a research nurse at the Lindner Research Center at 513-585-0844.

  • Anorexia in Advance Cancer

  • Breast Cancer

  • Colon Cancer

  • Head & Neck Cancer

  • Leukemia/Lymphoma

  • Lung Cancer

  • Molecular Analysis Therapy 

  • Oral Mucositis

  • Prostate Cancer

  • Registry

  • Solid Tumors

Anorexia in Advanced Cancer

NCT04803305

Pfizer C3651010-Study to Assess the Effect of PF-06946860 on Appetite Following Subcutaneous Administration to Patients with Anorexia and Advanced Cancer.  This is a 6 week, randomized, double-blind study.  Following this 6 week period, patients are eligible to continue to18 week open label treatment.

Breast Cancer

NCT02488967

NRG-BR003 NCT-#02488967, is a Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. The purpose of this trial is to determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer.

NCT03418961

SWOG 1501 NCT-#03418961, is a Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her-2+ Breast Cancer, Phase III. The purpose of this study is to assess whether prophylactic beta blocker therapy with Carvedilol compared with no prophylaxis reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab-based HER-2 targeted therapy.

NCT01901094

A011202 Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection.

NCT01905046

A211102 Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer

The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (early cell changes that are thought to be a marker of breast cancer risk) in women at increased risk for breast cancer. There will be testing for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. The study will compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better. 

Note: The standard drug used for the "breast cancer prevention" is tamoxifen. If the patient is eligible to take tamoxifen, he/she must be offered tamoxifen prevention as part of clinical care. Metformin and tamoxifen are not similar and function differently. This study is not investigating the use of tamoxifen. Metformin is not approved for preventing breast cancer, but is currently being tested to determine if it can prevent breast cancer.

Colon Cancer

NCT02912559

A021502 A Randomized Trial of Standard Chemotherapy Alone Or Combined With Atezolizumab As Adjuvant Therapy For Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair.

This study evaluates whether the addition of immune therapy to usual FOLFOX chemotherapy can improve patient outcome compared to FOLFOX alone. 

The immune therapy drug, atezolizumab, may allow ones immune system to do a better job of attacking the cancer cells in the body.

NCT01349881

S0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage0-III Colon  or Rectal Cancer, Phase III preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES).

NCT04264702

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer - The BESPOKE CRC study will prospectively enroll patients who have undergone surgery for stage II or III colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. 

Head & Neck Cancer

NCT03972527

LLD-001 Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of oral Mucositis in Adult Patients with Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy.

Leukemia/Lymphoma

NCT03420183

Oncternal CIRM-001 is a Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies. Cirmtuzumab is a novel therapeutic monoclonal antibody that targets ROR1, an onco-embryonic factor, expressed at high levels on CLL/SLL, MCL, and other tumors but not on normal adult tissues Nonclinical data support the development of cirmtuzumab together with ibrutinib to enhance antitumor activity, overcome disease resistance, and improve both short- and long-term outcomes for patients with CLL/SLL and MCL. The purpose of this study is to evaluate the safety and effectiveness of Cirmtuzumab, an investigational drug, which currently is not approved by the FDA.  It will be looked at alone as a single agent and in combination with ibrutinib, an FDA approved drug, in treating CLL/SLL or MCL.

UPDATE 1/4/21: CLL/SLL arm closed.  Recruiting Mantle Cell Lymphoma (MCL) only.

Lung Cancer

NCT04380636
 
Merck:  A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib Vs. Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. The primary hypotheses are:

  1. Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with olaparib is superior to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival (PFS) and overall survival (OS)

  2. Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab is superior to concurrent chemoradiation therapy followed by durvalumab with respect to PFS and OS

Molecular Analysis Therapy Choice


NCT02465060

EAY131 Molecular Analysis for Therapy Choice (MATCH) This study is a type of basket trial designed with the flexibility to open and close sub protocols. The study drugs included in this trial are specified by sub protocols and include single agents and combinations that have at least a recommended phase 2 dose. Patients enrolled on study will have a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial will be offered treatment on MATCH.

This trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

NCT03321981

A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors. This is a Phase I/II, open-label, single indication expansion group assignment study to assess the safety, tolerability, PK, PD, immunogenicity and antitumor activity of MCLA-128.

NCT03175224

A Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsAPL-101 is a novel, highly selective small molecule c-Met inhibitor (c-METi) that targets the c-Met -dysregulated pathway in several tumors.

NCT03263026

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™This study is being performed to evaluate an investigational drug called enzastaurin. Denovo Biopharma LLC, the study sponsor, has identified a unique marker found in individual human genes, called a biomarker, which appears to relate to a positive response to enzastaurin

NCT03947385

A phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusionsIDE196 is a potent, orally bioavailable, selective inhibitor of the PKC family of kinases and a second generation PKC inhibitor. It is rapidly absorbed across nonclinical species with a good tolerability profile. 

Oral Mucositis

NCT04595838

CHEM-01 A Randomized, Prospective, Multi-center Trial to Assess the Efficacy of a Cryotherapy Device vs. Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer

This study will compare the use of Chemo Mouthpiece TM along with best oral supportive care to best oral supportive care only in preventing and easing symptoms of chemotherapy related oral mucositis. Patients who are receiving protocol specified chemotherapy regimens will be randomly assigned to receive either study device and oral care ingredients or oral care ingredients only. All patients will complete daily questionnaires for the first 14 days of Cycles 1 and 2 of chemotherapy. Patients who are assigned to the study device will use the device during their chemotherapy infusion as well as at least twice a day at home for the first 7 days of Cycles 1 and 2 of chemotherapy. At the beginning of Cycle 3, patients that were not assigned to the study device will be given the option to receive study device for the remainder of their treatment.

Prostate Cancer

NCT03367702

NRG -GU005 Phase III IGRT and SBRT vs IGRT and hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer"

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

Registry Trials

MTG-022 Cancer cohort. Translational Medicine; Discovery and Evaluation of Biomarkers/Pharmacogenomics for the diagnosis and personalized management of patients. The purpose of this study is to collect tissue and blood samples for researchers  to study (analyze). The samples will be stored in a biobank and used by researchers to try to develop new drugs, new treatments or tests, as well as to study how individual differences may affect how drugs work.

Notable Labs Protocol N-01: An Observational Study to Collect and Assess Tissue Samples From Subjects With Documented Hematologic Malignancy (ANSWer) An observational study collecting blood samples and bone marrow aspirate during routine standard of care procedures for evaluation and tumor banking from subjects with hematological malignancies.

MT0291- SOP Cancer Co-hort. A study of Fresh/Frozen Blood, Fresh/Frozen Tissue and FFPE from patients with solid malignancies scheduled to receive I.O. Therapy (Opdivo, Keytruda, Tcentriq, or Yervoy alone or in combination including chemotherapy)

Solid Tumors 

NCT 04872166

BioTheryX-BTX-A51  This is a multicenter, open label, non-randomized, sequential dose escalation/cohort expansion, multiple dose study designed to evaluate the safety, toxicity, as well as preliminary efficacy of BTX-A51 in subjects with advanced solid tumors and Non Hodgkins Lymphoma. The study will be done in two phases.

Phase 1a (Dose Escalation Phase) and Phase 1b (Cohort Expansion Phase):

The Phase 1a portion is designed to determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of orally administered BTX-A51. BTX-A51 will be administered once daily on a weekly schedule of 5 days on/2 days off. Dose escalation will proceed according to a modified 3+3 design. 

NCT 04128423

Amphivena AMV 564-301 AMV564-301 is a Phase 1, open-label, multicenter dose-escalation with expansion trial in patients with locally advanced or metastatic solid tumors. In the dose-escalation portion of the study, cohorts of patients will receive AMV564 alone or in combination with Pembrolizumab at increasing dose levels to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion. In the expansion portion of the study, one or more cohorts of patients will receive AMV564 at the MTD or recommended dose to further evaluate safety, tolerability, and clinical activity.